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Methadone remains the most common form of pharmacological therapy for opioid dependence; however, there is a lack of
explanation for the reports of its relatively low success rate in achieving complete abstinence. One hypothesis is that in vivo binding
of methadone to the plasma glycoprotein alpha-1-acid glycoprotein (AGP), to a degree dependent on the molecular structure,
may render the drug inactive. This study sought to determine whether alterations present in the glycosylation pattern of AGP in
patients undergoing various stages of methadone therapy (titration < two weeks, harm reduction < one year, long-term > one and
a half years) could affect the affinity of the glycoprotein to bindmethadone.The composition of AGP glycosylation was determined
using high pH anion exchange chromatography (HPAEC) and intrinsic fluorescence analysed to determine the extent of binding to
methadone.Themonosaccharides galactose andN-acetyl-glucosamine were elevated in all methadone treatment groups indicating
alterations in AGP glycosylation. AGP from all patients receivingmethadone therapy exhibited a greater degree of binding than the
normal population. This suggests that analysing the glycosylation of AGP in patients receiving methadone may aid in determining
whether the therapy is likely to be effective.
1. Introduction
It has been reported that the number of people who could
be considered as being involved in opioid abuse, commonly
coadministeredwith the benzodiazepines (BDZs), is between
12.8 and 21.8 million individuals [1]. Opioid dependence
represents a universal problem to society and methadone
remains as the most common form of pharmacological ther-
apy. Similar to other drugs, the desired action of methadone
requires that itmust attain a certain in vivo concentration (the
minimally effective concentration, MEC) at its site of action
in order to provide a therapeutic effect. Unfortunately the
success rate of methadone in achieving complete abstinence
is poor and reportedly as low as 7% [2].
According to the free drug hypothesis, only a drug which
is in a free unbound state in vivo is active. As most drugs
access their target site of action through the bloodstream,
they come into contact with numerous plasma proteins in-
cluding albumin and 𝛼-1-acid glycoprotein (AGP), which are
capable of binding the drug and rendering it inactive. After
administration, methadone is strongly associated with AGP
[3], therefore, alterations in the level and structure of the pro-
tein could greatly affect the efficacy of the drug. When doses
of methadone are below the MEC, withdrawal symptoms
may arise, including nausea, anxiety, tremors and dissipation
of the euphoric “high” [4, 5]. Conversely, if concentrations
exceed the threshold too rapidly or by too much, the effects
of an overdose are displayed.
During the acute phase response to infection and disease,
levels of AGP are known to increase two- to fivefold [6]. The
increased production of AGP and any other drug binding
plasma proteins causes an immediate shift in the binding
equilibrium between drug and proteins upon the adminis-
tration of the drug [7]. Consequently, the plasma level of
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bioactive (unbound) drug available to the target site of action
or receptor is reduced, alongside its efficacy [8]. Rostami-
Hodjegan and colleagues [9] noted that in heroin-dependent
individuals with signs of opiate withdrawal, levels of AGP
were elevated and were thought to reduce the level of active
unbound methadone, promoting withdrawal symptoms.
Like many hepatically synthesised proteins, AGP is also
modified through the addition of oligosaccharide or glycan
chains (glycosylation). The process of glycosylation is an
ordered and functionally significant process which results in
a high degree of structural heterogeneity.The aforementioned
variability is essentially a result of different cell types pos-
sessing a diverse array of enzymes thus catalysing a range
of reactions to produce distinct glycans [10, 11]. AGP is exten-
sively glycosylated (45%) with five oligosaccharide chains
and exists in vivo as a heterogeneous population of variants
(glycoforms) owing to differing occupancy of the five gly-
cosylation sites by different oligosaccharide structures. Het-
erogeneity arises through subtle structural differences in
monosaccharide sequence and linkages, degree of branching
[bi-(2), tri-(3), tetra-(4) antennary], and the extent and
number of charged sialic acid groups (sialylation). Dur-
ing several physiological and pathological conditions, the
oligosaccharide “fingerprint” of AGP is altered [12, 13].
It is now widely accepted that AGP is an important drug-
binding protein in the serum as it binds both endogenous and
exogenous ligands.The drug-binding capabilities of AGP and
the binding site of human AGP have been well characterised
[14]. Muller [15] reported that AGP glycans are not critical in
the interaction with drugs at the binding site, and instead it
is solely dependent on the formation of the correct tertiary
structure, describing the folding of the protein into its three-
dimensional structure which is essentially determined by
the sequence of amino acids (primary structure). However,
although the drug binding site of AGP is peptide in nature,
the hydrodynamic mass and surface location of the oligosac-
charide chains are likely to affect the conformation, and
correct folding, of both the protein in general and the binding
site in particular. Therefore an alteration in the glycosylation
of AGP is likely to affect the extent of binding to drugs.
This study sought to investigate whether differences in the
relative level and glycosylation of AGP existed between that
isolated from opioid-dependent individuals and a “normal”
healthy population, which could correlate with variations in
the binding tomethadone.The structure of glycans expressed
by AGP was analysed using high pH anion exchange chro-
matography (HPAEC). Subsequently, fluorescence quench-
ing data was utilised as an indicator of binding tomethadone.
2. Materials and Methods
2.1. Materials. Cibacron Blue 3GA, Dulbecco’s phosphate-
buffered saline, dimethyl sulphoxide Glacial acetic acid, (±)-
methadone, polyethylene glycol (PEG) 3350, potassium chlo-
ride, potassium thiocyanate, Red Sepharose CL-6B, sodium
acetate, sodium azide, sodium chloride, theophylline, and
Trizma base were supplied by Sigma-Aldrich (Poole, UK).
Ethanol was purchased from Bamford Laboratories Ltd.,
(Norden Rochdale, UK). HPLC-grade water was obtained
from Rathburn Chemicals Ltd. (Walkerburn, UK). The poly
prep disposable 10mL columns were purchased from Bio-
Rad, (Hemel Hempstead, UK). Amicon Ultra-4 centrifugal
filter devices with a MW cutoff of 10,000 from Millipore
(UK) Ltd. sodium hydroxide (50% w/v) were supplied by
VWR International Ltd. (Lutterworth, UK). New England
Biolabs Inc., (Hertfordshire, UK) provided the peptide-N-
Glycosidase F (PNGase F) purified from Flavobacterium
meningosepticum, 10% NP-40, and NE Buffer G7. HPAEC-
PAD equipment, including the DX500 system and Carbopac
PA-100 column, was purchased from Dionex, Camberley,
UK. AGP N-linked glycan library was supplied by Prozyme
(Europa Bioproducts Ltd., Cambridgeshire, UK). Nunc (Ger-
many) supplied the 96-well microtitre plates, and A BMG
Labtech Optima fluorimeter (Germany) was used to analyse
the intrinsic fluorescence.
2.2. Methods. Ethical approval was granted by Lothian NHS
and Edinburgh Napier University Ethics committees which
allowed 2–5mL blood samples to be obtained from consent-
ing adults over 18 years of age (𝑛 = 20) undergoing various
stages of treatment for opioid addictions at the Commu-
nity Drug Problem Service (CDPS) in Edinburgh. Patient
demographics are summarised in Table 1. Individuals were
undergoing several phases including initial two-week titra-
tion (T), harm reduction (HR), or long-term methadone
treatment (LT) and had no concomitant conditions present.
Heparinised blood samples from “normal” healthy individu-
als were pooled by the blood transfusion service (BTS).
2.2.1. Isolation of AGP from Plasma. AGP was isolated from
all blood samples using protocols similar to those reported
by Elliott et al. [16]. SDS-PAGE indicated that the two-
column isolation technique generated relatively pure AGP.
Salt introduced during the isolation phase was removed using
centrifugal filter devices and HPLC-grade water.The levels of
isolated AGP were determined spectrophotometrically.
2.2.2. Monosaccharide Analysis. Preparation of the glycans
was similar to methods reported by Fan et al. [17]. AGP
(50𝜇g) was hydrolysed with 4M HCl (six hours) and 2M
TFA (four hours) separately; we also found that the use of
HCl rendered the neutral monosaccharides unstable over
long periods of time. Also, the TFA was thought to be too
weak to cleave N-acetylglucosamine (GlcNAc) residues from
the core—as demonstrated by a higher level of GlcNAc in
the presence of HCl compared to TFA. A Dowex cation-
exchange resin was used to purify the neutral monosac-
charides. HPAEC was used to separate and quantify the
monosaccharide components.
2.2.3. Oligosaccharide Analysis. Structural analysis was also
performed using HPAEC. Typically 100𝜇g of AGP was
denatured at 100∘C for three hours and the dried sample then
treated with a reaction mixture of HPLC-grade water (79%
v/v), NE Buffer G7 (10% v/v), NP-40 (10% v/v), and PNGaseF
(5U). The mixtures were incubated at 37∘C for 24 hours and
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Table 1: Patient demographics.
Stage of
therapy Identity Age Male/female
Methadone
dose (mg)
Titration
T1 32 F 95
T2 23 F 65
T3 37 F 55
T4 33 M 40
T5 20 M 60
Harm
reduction
HR1 37 F 90
HR2 28 M 85
HR3 23 F 150
HR4 23 F 150
Long term
LT1 35 M 95
LT2 33 M 150
LT3 36 F 40
LT4 44 F 90
LT5 30 M 105
LT6 51 M 85
LT7 34 M 150
LT8 42 M 50
LT9 34 M 150
LT10 31 M 200
LT11 30 M 90
then a further 5U of PNGase F was added. After a final 24-
hour incubation at 37∘C, ethanol precipitationwas performed
at 3 : 1 ratio with the reaction mixture.The samples were then
stored at −20∘C overnight and analysed by HPAEC.
2.2.4. Drug Binding Analysis. The binding of methadone to
the isolated AGP preparations was investigated using intrin-
sic fluorescence studies at the microtitre level. Commercial
AGP (5mg/mL) was dissolved in d-PBS and plated in 10 𝜇L
aliquots (𝑛 = 3). A range of theophylline (positive control)
andmethadone concentrations (0𝜇M–2500𝜇M)were added
in 10 𝜇L volumes—having been dissolved in DMSO. A final
reaction volume of 100 𝜇L was generated through the addi-
tion of D-PBS. Plates were excited at 280 nm and fluorescence
emitted at 340 nm (AGP maximum emission) recorded.
The experiment was repeated with AGP concentrations of
0.5m/mL to allow for the low levels of AGP isolated from
patient groups and ensures that the technique was adaptable
to this level. Commercial and isolated AGP was plated
(0.5mg/mL) and methadone standards added to include
values representing the therapeutic level of methadone (∼
4000 ng/mL) andothers out-with this; all were diluted tenfold
upon plating.
2.2.5. Statistical Analysis. Two sample 𝑡-tests and one-way
ANOVAs (with Tukey’s post hoc) were performed using
Minitab, version 15, to determine the statistical significance
of all quantitative data generated during the various analyses.
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Figure 1: Relative level of AGP isolated from treatment groups.
Summary of the mean level of AGP isolated from individuals at
different stages of methadone therapy. ∗Statistically different to
“normal” blood (𝑃 < 0.05).
3. Results and Discussion
3.1. AGP Levels. Using a set of standards, an AGP calibration
curve was generated and used to determine the relative
level of AGP isolated from the individual samples (Figure 1).
Statistical analysis was performed with two sample 𝑡-tests to
compare the relative difference between each patient group
and heparinised blood from a “normal” healthy population.
Significantly lower levels of AGP were isolated from the
“normal” blood population (𝑃 < 0.05) compared to those
from all other treatment groups. The levels of AGP were
found to be at least twofold higher which is comparable
with the increase in amounts reported after the acute phase
response [6].
3.2. Monosaccharide Analysis. The levels of monosaccharides
in the commercially purchased AGP were found (using one-
way ANOVA) to be greater (𝑃 < 0.05) than those in AGP iso-
lated from “normal” heparinised blood.However, direct com-
parisons were deemed invalid because the methods imple-
mented in the isolation of the glycoprotein differed. It was
considered more relevant to use the “normal” blood values
as comparisons, having been isolated by the same technique.
Therewas a significant change in the glycosylation ofAGP
in individuals receiving methadone as an opioid replace-
ment therapy compared to that from a “normal” healthy
population. The levels of galactose (Gal) and galactosamine
(GlcN; GlcNAc in the in vivo structure) were significantly
greater in patients undergoing methadone therapy when
compared to the “normal” group (refer to Figure 2). Relative
consistency was displayed in the level of mannose (Man)
between all samples which is consistent with its presence in
the complex N-linked oligosaccharide chains of AGP (three
mannose residues per chain).Themost significant differences
in monosaccharide composition occurred with respect to
the levels of galactose (Gal) and glucosamine (GlcN) which
suggests that there is an increase in the number of branches
on the oligosaccharide chains present. AGP has five N-linked
chains (so called because they are attached to the side chain of
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Figure 2: Mean level of monosaccharides in AGP glycans isolated
from treatment groups. “Normal blood” represents heparinised
blood from the Blood Transfusion Service. ∗Statistically significant
difference compared to normal heparinised blood sample (𝑃 < 0.05)
HR: harm reduction; LT: long-term treatment. Standard deviation
calculated from triplicate analysis of a single sample while others
were calculated from data from more than one patient (𝑛 = 4/+).
an asparagine amino acid) which can have a variable number
of branches attached to a core sequence. Since galactose
and the majority of glucosamine (as its acetylated form, N-
acetylglucosamine) are only present in the outer branches of
N-linked chains, an increase would tentatively suggest that
the degree of branching of a chain has also increased. Our
data suggests the occurrence of increased branching on the
chains of the AGP from themethadone replacement patients.
However, in the number of patients analysed, these changes
did not appear to be dependent upon stage or types of
opioid replacement therapy. The monosaccharide fucose
(Fuc), whose presence on oligosaccharide chains is generally
correlatedwith pathophysiological conditions such as inflam-
mation and cancer [18, 19] was not detected in any patient
sample.
3.3. Oligosaccharide Analysis. Oligosaccharide analysis using
HPAEC generated chromatograms which allowed qualita-
tive analysis. The technique initially separates enzymatically
cleaved glycans based on the degree of sialylation which pro-
vided the main negative charge. Glycans were separated into
charge bands, those expressing a single SA residue eluted first
(10–20minutes), followed by bisialylated (20–30minutes),
trisialylated (30–40minutes), and finally tetrasialylated, elut-
ing between 40 and 50 minutes. An AGP N-linked glycan
library was used to allow the corresponding charge groups
to be identified (Figure 3).
The glycosylation of AGP isolated from “normal” hep-
arinised blood samples was found to express numerous struc-
tures of different sialylation. Preference in this case appeared
to be for bisialylated forms. The traces generated for the
oligosaccharides of titration patients indicated that bi- and
trisialylated structures were most common although not
the only type present. This was similar to the “normal”
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Figure 3: Oligosaccharide library trace generated during separation
by HPAEC. Separation based on the charge of oligosaccharide
chains asmeasured using nano-Coulomb (nC). Degree of sialylation
highlighted in a dashed line.
and commercial samples, implying low levels of branching.
Long-term patient AGP was also found to show a greater
proportion of bi- and trisialylated structures, however, unlike
the titration phase individuals, peaks in the tetrasialylated
region were more defined (e.g., LT4, LT9, and LT10). In many
patients, the number of peaks was fairly low but theywere of a
large size suggesting that there were many of the same glycan
expressed.
Overall, it was shown that similarities existed between the
treatment and nontreatment groups. Titration and “normal”
appeared to have a high proportion of trisialylated structures.
Variation existed, particularly within the LT group; some
AGP displaying more highly branched structures (e.g., LT4
and LT10) while others having a greater proportion of less-
sialylated structures (e.g., LT3).
3.4. Drug Binding. The degree of fluorescence quench-
ing increased as the concentration of methadone added
was increased, reaching a plateau at concentrations above
∼100 𝜇Minboth patientAGPand that isolated from“normal”
heparinised samples. Values in the absence and presence of
1.07 𝜇M and 250 𝜇M of methadone are recorded in Table 2
to highlight the similarity of participant AGP with that from
“normal” hepatrinised blood in the absence of drug. The rate
of reduction in fluorescence was most pronounced at low
concentrations indicating that binding became saturated rel-
atively quickly. However, the drug did not completely quench
the intrinsic fluorescence; some binding sites remained
available. In general, the overall reduction in fluorescence
was greater for all patient AGP samples analysed when
compared to “normal” AGP, however, there were no clear
differences between patients. Further studies are required to
allow quantification and statistical analysis of binding, and
this study was to allow preliminary comparison.
4. Conclusion
The success of drug therapies relies on the presence of
specific concentrations of its bioactive form (MEC) at the
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Table 2: Intrinsic fluorescence of AGP in absence and presence of 1.07𝜇M and 250 𝜇Mmethadone.
Sample Fluorescence in the absenceof methadone (RFU)
Fluorescence in the presence of
1.07 𝜇Mmethadone (RFU)
Fluorescence in the presence of
250 𝜇Mmethadone (RFU)
Commercial (sigma) 41636 38236 30620
“Normal” 1 39943.5 39021 35476
“Normal” 2 37784.5 37032 36138
T1 39859 34006 30712
T2 35992 33371 30840
T3 36715 33020 30284
T4 37571 31089 29182
T5 38882 33959 29412
HR1 39107 33280 29289
HR2 38438 33215 29025
HR3 33531 30023 27072
LT1 31770 30775 27196
LT2 33324 30252 28346
LT4 38688 37189 31008
LT5 39937 36241 31893
LT6 39691 31681 27137
LT7 38484 31538 28658
corresponding site of action. Numerous factors determine
whether this can be achieved; however, often overlooked is
the binding to plasma proteins. Of primary interest to this
study was whether the level and glycoform expression of
AGP isolated from patients undergoing various stages and
types of substitute therapy for opioid dependence differed to a
“normal” healthy population. It was supposed that alterations
may correlate to variations in the binding of the glycoprotein
to methadone. It was hypothesised that AGP isolated from
patients would exhibit higher levels and structural changes
causing increased binding to methadone when compared
to a “normal” AGP sample. Greater binding would at least
partially explain why high doses of the drug are required—
accounting for that which is bound and therefore inactivated.
Similar to research undertaken by Rostami-Hodjegan
et al. [9], the current study detected increased levels of AGP
expressed in individuals who displayed signs of withdrawal
from heroin (represented by the titration group). The lev-
els isolated from the patients in the remaining treatment
groups—excluding the individual receiving heroin—were
also greater than that isolated from the “normal” population.
Our study seeks to extend this research by examining the
effect of the glycosylation pattern of AGP, and any changes
and correlating to the extent of binding to methadone.
Altered glycosylation of AGP has been widely studied in
a number of pathophysiological conditions (see reviews in
[6, 14]) and compared with the pattern present in healthy
subjects which tends towards chains with either two (bi-)
or three (tri-) branches. A decrease in the aforementioned
number of branches has been demonstrated in acute inflam-
matory conditions while increased branching is observed to
be associated with chronic inflammations, liver diseases, and
poor prognosis in cancer after surgery.The data from the cur-
rent study suggests that AGP isolated from all phases of the
methadone treatment programme is associated with a shift
towards increased branching. The mixture of isolated glycan
chains is separated, by HPAEC, according to the number of
terminal negatively charged sialic acids possessed which can
normally be directly correlated with the size of the chains.
In other words a bi-sialylated structure contains two sialic
acid residues which equates to one terminating each of two
branches; a tri-sialylated structure has three sialic acids on
typically three branches, and a tetra-sialylated chain has four
branches each terminated with a sialic acid. Our results indi-
cate that AGP isolated from subjects in the titration and long-
term phases both had increases in the tri-sialylated/three
branch population, and the latter also contained significant
quantities of tetra-sialylated chains with four branches. The
significance of these alterations with respect to the drug bind-
ing is likely to be related to changes in the conformation of
the drug binding site of AGP resulting in either decreased or
increased binding affinity for methadone. An increased bind-
ing affinity for methadone would result in a larger percentage
of the free drug being bound therefore reducing or completely
abolishing the desired therapeutic response.
Although it is well understood that structural changes to
AGP glycosylation can significantly affect the functions of
the biomolecule, there is currently a paucity of research data
pertaining to this effect in patients undergoing opioid-
replacement therapy. It is well understood that AGP generally
exhibits a degree of selectivity for the ligands to which it
binds, and, in terms of drugs, they are generally of the neutral
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or basic variety [8, 14]. If binding to methadone is altered by
structural modifications to the glycan chains present on AGP,
the free active concentrations and subsequent pharmacolog-
ical effect could be changed. A reduction in efficacy would
become apparent when the affinity increases or vice versa if
the affinity was reduced.
Currently treatment is based on a titration phase where
individuals are given low doses of drug to allow for its slow
accumulation. Finally, a maintenance dose is determined.
However, with investigations like these it may be possible to
determine the relative level of glycoforms expressed by an
individual’s AGP to identify those where it is less likely to be
effective or where higher doses will be required. Also, another
consequence of i.v heroin use is collapsed veins, complicating
venipuncture. However, this preliminary study has shown
that potential correlation exists between the structure of AGP
glycans and its ability to bind the basic drug methadone
although a larger patient population is required to address
other influential factors and determine whether the interac-
tion could significantly affect the efficacy ofmethadone in the
treatment of opioid dependencies.
The variability in the binding of methadone to AGP may
partly explain why some individuals require more drug than
others to produce the effect. That is not to forget the roles
of metabolism and elimination which display interindividual
variability due to differences in gene expression. Furtherwork
is required to quantify the degree of methadone binding to
AGP with specific glycosylation patterns. Fortunately, the
ability to quantify the interaction between a plasma protein
such as AGP and a drug has recently improved through the
use of surface plasma resonance (SPR) [20] which overcomes
the limitations of previous methods such as equilibrium
dialysis, ultrafiltration, and ultracentrifugation. The latter
methods are associated with problems of cost, throughput,
and quality of information obtained, as well as being equilib-
rium based and, therefore, providing no kinetic information.
The use of SPR not only overcomes these limitations but also
allows the more accurate statistical analysis of the correlation
between the degree of binding and drug efficacy.
Conflict of Interests
There is no conflict of interests with any of the authors (nor
did any of them gain financially).
Acknowledgment
The authors acknowledge the support of the Carnegie Trust
for the Universities of Scotland in the award of a Caledonian
research scholarship to Jennifer L. Behan.
References
[1] UNODC, World Drug Report 2010, Sales No.E.10.XI.13, United
Nations Publication, 2010.
[2] N. McKeganey, M. Bloor, M. Robertson, J. Neale, and J.
MacDougall, “Abstinence and drug abuse treatment: results
from the drug outcome research in Scotland Study,” Drugs, vol.
13, no. 6, pp. 537–550, 2006.
[3] M. K. Romach, K. M. Piafsky, and J. G. Abel, “Methadone bind-
ing to orosomucoid (𝛼1-acid glycoprotein): determinant of free
fraction in plasma,” Clinical Pharmacology and Therapeutics,
vol. 29, no. 2, pp. 211–217, 1981.
[4] O. Drummer and M. Odell, The Forensic Pharmacology Drugs
of Abuse, Edited by O. H. Drummer, Hodder Arnold, 2001.
[5] M. M. Scimeca, S. R. Savage, R. Portenoy, and J. Lowinson,
“Treatment of pain in methadone-maintained patients,”Mount
Sinai Journal of Medicine, vol. 67, no. 5-6, pp. 412–422, 2000.
[6] F. Ceciliani and V. Pocacqua, “The acute phase protein 𝛼1-acid
glycoprotein: a model for altered glycosylation during diseases,”
Current Protein and Peptide Science, vol. 8, no. 1, pp. 91–108,
2007.
[7] Y. Kuroda, S. Matsumoto, A. Shibukawa, and T. Nakagawa,
“Capillary electrophoretic study on pHdependence of enantios-
elective disopyramide binding to genetic variants of human 𝛼1-
acid glycoprotein,” Analyst, vol. 128, no. 8, pp. 1023–1027, 2003.
[8] J. M. H. Kremer, J.Wilting, and L. H.M. Janssen, “Drug binding
to human alpha-1-acid glycoprotein in health and disease,”
Pharmacological Reviews, vol. 40, no. 1, pp. 1–47, 1988.
[9] A. Rostami-Hodjegan, K. Wolff, A. W. M. Hay, D. Raistrick,
R. Calvert, and G. T. Tucker, “Population pharmacokinetics of
methadone in opiate users: characterization of time-dependent
changes,” British Journal of Clinical Pharmacology, vol. 48, no. 1,
pp. 43–52, 1999.
[10] A. Varki, R. D. Cummings, J. D. Esko et al., Essentials of Gly-
cobiology, Cold Spring Harbour Laboratory Press, 2nd edition,
2009.
[11] M. E. Taylor and K. Drickamer, Introduction to Glycobiology,
Oxford University Press Limited, 2003.
[12] W. van Dijk, G. A. Turner, and A. Mackiewicz, “Changes in
glycosylation of acute-phase proteins in health and disease:
occurrence, regulation and function,” Glycosylation and Dis-
ease, vol. 1, no. 1, pp. 5–14, 1994.
[13] K. Higai, Y. Aoki, Y. Azuma, and K. Matsumoto, “Glycosylation
of site-specific glycans of 𝛼1-acid glycoprotein and alterations in
acute and chronic inflammation,”Biochimica et Biophysica Acta,
vol. 1725, no. 1, pp. 128–135, 2005.
[14] Z.H. Israili and P. G.Dayton, “Human alpha-1-glycoprotein and
its interactions with drugs,” Drug Metabolism Reviews, vol. 33,
no. 2, pp. 161–235, 2001.
[15] W. E. Muller, “Stereoselective plasma protein binding of drugs,”
inDrug Stereochemistry: AnalyticalMethods and Pharmacology,
I. W.Wainer and D. E. Drayer, Eds., p. 277, Marcel Dekker, New
York, NY, USA, 1988.
[16] M. A. Elliott, H. G. Elliott, K. Gallagher, J. McGuire, M.
Field, and K. D. Smith, “Investigation into the concanavalin A
reactivity, fucosylation and oligosaccharidemicroheterogeneity
of 𝛼1-acid glycoprotein expressed in the sera of patients with
rheumatoid arthritis,” Journal of Chromatography B, vol. 688,
no. 2, pp. 229–237, 1997.
[17] J.-Q. Fan, Y. Namiki, K. Matsuoka, and Y. C. Lee, “Comparison
of acid hydrolytic conditions for Asn-linked oligosaccharides,”
Analytical Biochemistry, vol. 219, no. 2, pp. 375–378, 1994.
[18] G. A. Turner, A. W. Skillen, and P. Buamah, “Relation between
raised concentrations of fucose, sialic acid, and acute phase
proteins in serum from patients with cancer: choosing suitable
serum glycoprotein markers,” Journal of Clinical Pathology, vol.
38, no. 5, pp. 588–592, 1985.
BioMed Research International 7
[19] J. J. Listinsky, G. P. Siegal, and C. M. Listinsky, “Alpha-L-fucose:
a potentially critical molecule in pathologic processes including
neoplasia,” American Journal of Clinical Pathology, vol. 110, no.
4, pp. 425–440, 1998.
[20] S. S. Gustafsson, L. Vrang, Y. Terelius, and U. H. Danielson,
“Quantification of interactions between drug leads and serum
proteins by use of ‘binding efficiency’,” Analytical Biochemistry,
vol. 409, no. 2, pp. 163–175, 2011.
